SRPT241220C85000
- 25.65
- 0.000.00%
Sarepta Therapeutics Newsroom
Sarepta Therapeutics Analyst Ratings
Sarepta Therapeutics Is Maintained at Sell by HC Wainwright & Co.
H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Cuts Target Price to $75
Sarepta Therapeutics: Sell Rating Amid Uncertain Pipeline and Financial Risks
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Sarepta Therapeutics: Strong Buy Rating Amid Strategic Partnership and Promising Growth Potential
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $182 to $215
RBC Capital Remains a Buy on Sarepta Therapeutics (SRPT)
Sarepta Therapeutics Is Maintained at Overweight by Piper Sandler
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $182 to $217
Sarepta Therapeutics (SRPT) Gets a Buy From TD Cowen
Sarepta Therapeutics Analyst Ratings
Sarepta Therapeutics Receives Buy Rating From Gil Blum: Strategic Partnerships and Financial Stability Highlight Growth Potential
Sarepta Therapeutics: Strategic Expansion and Robust Pipeline Justify Buy Rating and $217 Price Target
Sarepta Therapeutics' Strategic Partnership With Arrowhead Signals Strong Growth Prospects: A Buy Recommendation
Oppenheimer Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
Sarepta Therapeutics Analyst Ratings
H.C. Wainwright Initiates Sarepta Therapeutics(SRPT.US) With Sell Rating, Announces Target Price $80
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $197
Barclays Initiates Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $209